Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

steris plc (ireland) - STE

STE

Close Chg Chg %
210.59 5.08 2.41%

Closed Market

215.67

+5.08 (2.41%)

Volume: 1.23M

Last Updated:

Jun 26, 2026, 3:59 PM EDT

Trade Now

Company Overview: steris plc (ireland) - STE

STE Key Data

Open

$212.54

 Day Range

212.06 - 216.42

52 Week Range

198.01 - 269.39

 Market Cap

$20.52B

Shares Outstanding

97.46M

 Public Float

97.13M

Beta

0.93

 Rev. Per Employee

N/A

P/E Ratio

26.57

 EPS

$7.97

Yield

116.81%

 Dividend

$0.63

EX-DIVIDEND DATE

Jun 8, 2026

 SHORT INTEREST

N/A

AVERAGE VOLUME

881.57K

  

STE Performance

1 Week
 
 6.45%
 
1 Month
 
 1.38%
 
3 Months
 
 -1.70%
 
1 Year
 
 -9.68%
 
5 Years
 
 4.29%
 

STE Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 11
Full Ratings ➔

About steris plc (ireland) - STE

STERIS Plc engages in the provision of healthcare and life science products and service solutions. It operates through the following segments: Healthcare, Life Sciences, Applied Sterilization Technologies, and Dental. The Healthcare segment provides a comprehensive offering for healthcare providers worldwide, focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites. The Life Sciences segment designs, manufactures, and sells consumable products, equipment maintenance, specialty services, and capital equipment. The Applied Sterilization Technologies segment is involved in contract sterilization and testing services for medical device and pharmaceutical manufacturers. The Dental segment offers a comprehensive offering for dental practitioners and dental schools, offering instruments, infection prevention consumables and instrument management systems. The company was founded in 1985 and is headquartered in Dublin, Ireland.

STE At a Glance

STERIS Plc (Ireland)
70 Sir John Rogerson's Quay
Dublin, Dublin 2
Phone N/A Revenue 5.94B
Industry Medical Specialties Net Income 782.30M
Sector Health Technology 2026 Sales Growth 8.726%
Fiscal Year-end 03 / 2027 Employees 17,937
View SEC Filings

STE Valuation

P/E Current 26.571
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 27.899
Price to Sales Ratio 3.677
Price to Book Ratio 3.011
Price to Cash Flow Ratio 16.27
Enterprise Value to EBITDA 14.377
Enterprise Value to Sales 3.957
Total Debt to Enterprise Value 0.089

STE Efficiency

Revenue/Employee 330,930.479
Income Per Employee 43,613.759
Receivables Turnover 5.432
Total Asset Turnover 0.568

STE Liquidity

Current Ratio 2.091
Quick Ratio 1.54
Cash Ratio 0.384

STE Profitability

Gross Margin 44.829
Operating Margin 19.325
Pretax Margin 17.643
Net Margin 13.179
Return on Assets 7.492
Return on Equity 11.348
Return on Total Capital 8.438
Return on Invested Capital 8.808

STE Capital Structure

Total Debt to Total Equity 29.054
Total Debt to Total Capital 22.513
Total Debt to Total Assets 19.438
Long-Term Debt to Equity 26.90
Long-Term Debt to Total Capital 20.844
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Steris Plc (ireland) - STE

Collapse All in section
All values USD millions. 2023 2024 2025 2026 5-year trend
Sales/Revenue
4.96B 5.14B 5.46B 5.94B
Sales Growth
+8.13% +3.65% +6.24% +8.73%
Cost of Goods Sold (COGS) incl D&A
2.79B 2.90B 3.04B 3.27B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
552.90M 565.24M 476.21M 486.50M
Depreciation
173.15M 296.93M 200.02M 218.30M
Amortization of Intangibles
379.75M 268.32M 276.19M 268.20M
COGS Growth
+8.63% +3.80% +4.82% +7.72%
Gross Income
2.16B 2.24B 2.42B 2.66B
Gross Income Growth
+7.50% +3.46% +8.09% +10.00%
Gross Profit Margin
+43.63% +43.55% +44.31% +44.83%
2023 2024 2025 2026 5-year trend
SG&A Expense
1.38B 1.33B 1.43B 1.51B
Research & Development
101.58M 103.68M 107.65M 112.90M
Other SG&A
1.28B 1.23B 1.33B 1.40B
SGA Growth
-0.49% -3.86% +7.70% +5.67%
Other Operating Expense
- - - -
-
Unusual Expense
512.58M 69.79M 118.96M 45.10M
EBIT after Unusual Expense
267.08M 838.05M 867.55M 1.10B
Non Operating Income/Expense
(1.74M) 9.11M 14.92M 6.00M
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
107.99M 144.35M 86.26M 60.70M
Interest Expense Growth
+20.53% +33.67% -40.24% -29.63%
Gross Interest Expense
114.36M 151.44M 93.42M 72.70M
Interest Capitalized
6.37M 7.09M 7.16M 12.00M
Pretax Income
157.35M 702.81M 796.21M 1.05B
Pretax Income Growth
-49.97% +346.66% +13.29% +31.54%
Pretax Margin
+3.17% +13.68% +14.58% +17.64%
Income Tax
51.53M 149.53M 184.65M 262.20M
Income Tax - Current - Domestic
171.44M 159.73M 177.54M 200.30M
Income Tax - Current - Foreign
70.28M 58.92M 64.17M 78.80M
Income Tax - Deferred - Domestic
(165.05M) (54.71M) (48.13M) (7.40M)
Income Tax - Deferred - Foreign
(25.14M) (14.41M) (8.92M) (9.50M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
105.81M 553.28M 611.56M 785.10M
Minority Interest Expense
(1.22M) 1.84M 1.43M 2.80M
Net Income
107.03M 551.44M 610.12M 782.30M
Net Income Growth
-56.12% +415.22% +10.64% +28.22%
Net Margin Growth
+2.16% +10.73% +11.18% +13.18%
Extraordinaries & Discontinued Operations
- - (173.20M) 18.51M
-
Discontinued Operations
- - (173.20M) 18.51M
-
Net Income After Extraordinaries
107.03M 378.24M 628.64M 782.30M
Preferred Dividends
- - - -
-
Net Income Available to Common
107.03M 378.24M 628.64M 782.30M
EPS (Basic)
1.0735 3.8288 6.3772 7.9664
EPS (Basic) Growth
-57.07% +256.67% +66.56% +24.92%
Basic Shares Outstanding
99.71M 98.79M 98.58M 98.20M
EPS (Diluted)
1.0677 3.8068 6.3454 7.926
EPS (Diluted) Growth
-56.95% +256.54% +66.69% +24.91%
Diluted Shares Outstanding
100.25M 99.36M 99.07M 98.70M
EBITDA
1.33B 1.47B 1.46B 1.63B
EBITDA Growth
+13.40% +10.55% -0.70% +11.68%
EBITDA Margin
+26.88% +28.67% +26.79% +27.52%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 287.333
Number of Ratings 11 Current Quarters Estimate 2.503
FY Report Date 06 / 2026 Current Year's Estimate 11.162
Last Quarter’s Earnings 2.83 Median PE on CY Estimate N/A
Year Ago Earnings 10.17 Next Fiscal Year Estimate 12.189
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 7 7 7 7
Mean Estimate 2.50 2.70 11.16 12.19
High Estimates 2.58 2.75 11.22 12.42
Low Estimate 2.45 2.66 11.08 11.99
Coefficient of Variance 1.91 1.19 0.43 1.10

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 6 5 5
OVERWEIGHT 2 2 2
HOLD 3 3 3
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Steris Plc (ireland) - STE

Date Name Shares Transaction Value
Nov 21, 2025 Renato G. Tamaro V.P. & Corporate Treasurer 10,731 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $182.22 per share 1,955,402.82
Nov 21, 2025 Renato G. Tamaro V.P. & Corporate Treasurer 7,407 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $257.43 per share 1,906,784.01
Nov 21, 2025 Renato G. Tamaro V.P. & Corporate Treasurer 7,195 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $258.03 per share 1,856,525.85
Nov 21, 2025 Renato G. Tamaro V.P. & Corporate Treasurer 5,695 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $257.76 per share 1,467,943.20
Nov 21, 2025 Renato G. Tamaro V.P. & Corporate Treasurer N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Aug 13, 2025 Mohsen M. Sohi Director 26,471 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $64.05 per share 1,695,467.55
Aug 13, 2025 Louis A. Shapiro Director 975 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 13, 2025 Paul E. Martin Director 4,562 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 13, 2025 Mohsen M. Sohi Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Aug 13, 2025 Mohsen M. Sohi Director 7,750 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 13, 2025 Mohsen M. Sohi Director 7,244 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 13, 2025 Mohsen M. Sohi Director 2,226 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 13, 2025 Mohsen M. Sohi Director 22,361 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $241.96 per share 5,410,467.56
Aug 13, 2025 Cynthia L. Feldmann Director 8,128 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 13, 2025 Cynthia L. Feldmann Director 1,407 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 13, 2025 Nirav R. Shah Director 6,503 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 13, 2025 Cynthia L. Feldmann Director 4,200 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Aug 13, 2025 Christopher S. Holland Director 4,964 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 13, 2025 Richard Carroll Breeden Director 19,545 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 13, 2025 Richard Carroll Breeden Director 19,190 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Steris Plc (Ireland) in the News